1. Circulating Epstein-Barr virus microRNAs BART7-3p and BART13-3p as novel biomarkers in nasopharyngeal carcinoma
- Author
-
Jingfeng Zong, Yuhong Zheng, Ying Su, Jianji Pan, Cheng Lin, Chen Mengyuan, Honglin Chen, Shaojun Lin, Tianzhu Lu, Qiaojuan Guo, Yixin Chen, Yunbin Ye, Yuanji Xu, Keyu Lin, and Yan Chen
- Subjects
0301 basic medicine ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Herpesvirus 4, Human ,Epstein‐Barr virus ,medicine.disease_cause ,Gastroenterology ,Virus ,Metastasis ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Clinical Research ,Internal medicine ,Biomarkers, Tumor ,Medicine ,Humans ,metastasis ,Circulating MicroRNA ,Aged ,Nasopharyngeal Carcinoma ,microRNA ,business.industry ,Proportional hazards model ,Hazard ratio ,Nasopharyngeal Neoplasms ,General Medicine ,Original Articles ,Middle Aged ,medicine.disease ,Prognosis ,Epstein–Barr virus ,Survival Analysis ,030104 developmental biology ,Real-time polymerase chain reaction ,Oncology ,Nasopharyngeal carcinoma ,030220 oncology & carcinogenesis ,DNA, Viral ,Biomarker (medicine) ,RNA, Viral ,biomarker ,Female ,Original Article ,business - Abstract
Epstein‐Barr virus (EBV) BamHI A rightward transcripts (BART) encoded microRNAs (EBV‐miR‐BARTs) are abnormally highly expressed in nasopharyngeal carcinoma (NPC). This study aims to investigate the diagnostic and prognostic performance of miR‐BART7‐3p and miR‐BART13‐3p. Plasma levels of EBV DNA, miR‐BART7‐3p, and miR‐BART13‐3p were examined by quantitative PCR in 483 treatment‐naïve NPC patients and 243 controls without NPC. The prognostic performance was examined by comparing plasma levels with rates of distant metastasis during follow‐up. The area under the receiver operating characteristic curve for diagnosing NPC was 0.926 for EBV DNA, 0.964 for plasma miR‐BART7‐3p, 0.973 for miR‐BART13‐3p, and 0.997 for all three indices. Among 465 NPC patients without distant metastasis, the above‐median miR‐BART7‐3p and EBV DNA were independent risk for shorter distant metastasis‐free survival (DMFS) (hazard ratio [HR] = 2.94, 95% confidence interval [CI], 1.44‐5.97, P = .003; HR = 2.27, 95% CI, 1.26‐4.10, P = .006) in multivariate Cox regression. Epstein‐Barr virus DNA, miR‐BART7‐3p, and miR‐BART13‐3p after radiotherapy were detectable in 28.6%, 17.6%, and 54.7% of patients, respectively. In multivariate Cox regression, detectable miR‐BART7‐3p and EBV DNA were independent risks for shorter DMFS (HR = 4.13, 95% CI, 1.89‐9.01, P, This is so far the most extensive retrospective study to report the diagnostic and prognostic value of circulating levels of the Epstein‐Barr virus BamHI A rightward transcripts encoded microRNAs (EBV miR‐BARTs) in nasopharyngeal carcinoma. Compared with circulating EBV DNA, this study found that circulating EBV miR‐BARTs is not inferior to EBV DNA in diagnosis and prognosis. Furthermore, the combination of circulating levels of EBV DNA and miR‐BARTs at diagnosis can improve the potential for diagnostic and prognostic evaluation.
- Published
- 2020